ALK and lung adenocarcinoma: Our study findings were supported by the work of Jan Budczies et al., who showed that the specific immunosuppressive characteristics of ALK- and EGFR-positive lung adenocarcinoma suggest further clinical evaluation of immune modulators as partners of ICBs in such tumors (48).